Gyroscope Therapeutics
Asim A. Siddiqui is a seasoned professional in the field of translational medicine and clinical research, currently serving as Principal Scientist II at Novartis since January 2023. Prior experience includes leadership roles in biomarker development at Gyroscope Therapeutics and positions at AstraZeneca, where Asim held various responsibilities in clinical pharmacology and bioanalysis. Additional professional history encompasses senior scientific roles at Covance and MICRON RESEARCH LIMITED, as well as an associate scientist role at AstraZeneca. Asim's academic background includes a PhD in Interdisciplinary Biotechnology from the All India Institute of Medical Sciences and a certification in Clinical Trials Design and Management from the University of California, Santa Cruz, complemented by Master's and Bachelor's degrees in Biochemistry from AMU University.
Gyroscope Therapeutics
Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare diseases to treat a leading cause of blindness, dry age-related macular degeneration (AMD).